Selank 5mg Neuropeptides

This fundamental difference is explained by non-benzodiazepine mechanisms: GABAergic system modulation via tuftsin receptors, enkephalinase inhibition, increased BDNF expression, potentiation of cortical noradrenergic and dopaminergic systems. Selank is thus often characterised in Russian literature as an "atypical anxiolytic" or "regulator of neuropsychic homeostasis".

This vial delivers 5 mg of high-purity Selank (>98 %, HPLC) in lyophilised form, type I borosilicate glass, fluorinated butyl stopper. Destined exclusively for in vitro research and preclinical studies on non-human models, in accordance with European regulations; no human, dietary or medical use. The product is not approved as a medication in the European Union.

This product is not intended for human use. The protocols described are examples drawn from Russian scientific literature and documented medication practices in Russia, provided strictly for informational purposes for research work on non-human models.

Sealed unreconstituted vialIn the fridge (+2 to +8 °C); for long-term storage (over 3 months), a -20 °C freezer is an option, stability 24 months. At 2-8 C, stability 12 months. At room temperature (20-25 C), maximum 30 days stability; beyond, accelerated hydrolysis of peptide bonds.

For intranasal useSelank can be transferred to a clean nasal spray vial (pharmacy type, 10-30 ml). Dilution possible in sterile physiological saline to reach commercial Selanc concentration (0.15 % = 1.5 mg/ml). Stability 7-14 days refrigerated.

Laboratory documentationReconstitution date, COA lot, storage conditions, administration device used, to be recorded for traceability.

Selank's mechanism of action unfolds along at least five axes, documented primarily by the Russian school of neuropeptidology.

First axis, indirect GABAergic modulation. Kozlovskaya 2003 showed that Selank, although it does not bind directly to the GABA-A receptor (unlike benzodiazepines), increases GABA-A expression in rat cortex and hippocampus after intranasal administration. This is downstream transcriptional modulation, without direct activation of the chloride channel. This difference explains why Selank is anxiolytic without sedation, without amnesia and without tolerance.

Second axis, enkephalinase (aminopeptidase N) inhibition. Zolotov 1997 Bull Exp Biol Med demonstrated in vitro that Selank inhibits plasma enkephalinase, the enzyme that degrades endogenous enkephalins. The result is an elevation of circulating enkephalin levels (Met-enkephalin, Leu-enkephalin), endogenous opioid pentapeptides that modulate mood, anxiety and pain. This indirect opioid-mimetic action is probably one of the major substrates of the anxiolytic effect.

Third axis, regulation of BDNF (Brain-Derived Neurotrophic Factor) expression. Inozemtseva 2008 and Volkova 2016 Front Pharmacol showed by RT-PCR that Selank increases BDNF expression in rat hippocampus, an effect shared with SSRI antidepressants (fluoxetine) and tricyclic antidepressants. BDNF modulates neuroplasticity, adult neurogenesis and stress resilience circuits. This axis potentially explains the nootropic and pro-cognitive effects reported by users.

Fourth axis, monoaminergic modulation. Medvedev 2014 BioMed Res Int characterised by in vivo cerebral microdialysis in rats that Selank increases extracellular levels of noradrenaline and dopamine in the prefrontal cortex, without significant effect on serotonin. This monoaminergic signature resembles noradrenaline-dopamine inhibitors (bupropion) rather than SSRIs, and corresponds to the "anxiolytic without sedation" clinical profile: preserved attention, preserved wakefulness, concentration possible.

Selank has a scientific corpus primarily Russian of approximately 80 publications, including several controlled Russian clinical trials and half a dozen English-language publications in PubMed-indexed journals.

Initial development and tuftsinFridkin 1970 Biochim Biophys Acta isolated endogenous tuftsin from the spleen. Identification of tuftsin as a neuroimmune regulator motivated the synthesis of stabilised derivatives, culminating in Selank in 1989 (Russian Myasoedov patent). Ashmarin 1997 Patol Fiziol Eksp Ter described the first preclinical data on anxiolytic activity.

Neuromodulation and BDNFVolkova 2016 Front Pharmacol is one of the few quality English-language publications, characterising Selank's effects on neuronal gene expression (BDNF, GABA-A, monoamine enzymes) by RT-PCR and DNA chips in neuronal culture and in rats in vivo.

Nootropic effectsSemenova 2007 and Koroleva 2012 studied Selank in learning and memory paradigms (Morris water maze, passive avoidance). Results: improvement in memory retention in stressed rats, facilitated mnesic consolidation. Users anecdotally report improvement in concentration and cognitive fluidity, but formal human nootropic data are limited.

Addictions and withdrawalKozlovskaya 2000 tested Selank in opioid and alcohol withdrawal protocols in rats, observing a reduction in seeking behaviours and attenuation of withdrawal symptoms. In humans, observational series suggested utility in supporting tobacco and alcohol withdrawal, but without a conclusive randomised trial.

COVID-19Sluzhaeva 2022 and Blagonravova 2022 published Russian series on the use of Selank in reducing post-COVID anxiety and improving post-infectious cognitive recovery. Observational data, no randomised trial.

Critical limitationAlmost all the corpus is Russian, often in journals not indexed in PubMed, with sometimes limited trial designs (cohort size, absence of placebo, evaluation bias). Independent Western replication is minimal. The non-European regulatory status limits formal applications.